A new malaria drug, Ganaplacide/Lumefantrine, shows over 97% cure rates in trials. This treatment is effective even where current medicines are failing. The drug targets parasite transmission, potentially reducing spread. Novartis plans regulatory submission soon. If approved, it could significantly advance global malaria control efforts.
